AEON Biopharma’s (AEON) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of AEON Biopharma (NASDAQ:AEON) in a report published on Wednesday, Benzinga reports. They currently have a $18.00 price objective on the stock. HC Wainwright also issued estimates for AEON Biopharma’s Q1 2024 earnings at ($0.31) EPS, Q2 2024 earnings at ($0.31) EPS, Q3 2024 earnings at ($0.32) EPS, Q4 2024 earnings at ($0.24) EPS, FY2024 earnings at ($1.18) EPS, Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.24) EPS and FY2025 earnings at ($1.16) EPS.

AEON Biopharma Price Performance

AEON opened at $4.66 on Wednesday. The firm has a 50 day simple moving average of $10.55 and a 200 day simple moving average of $7.78. AEON Biopharma has a fifty-two week low of $3.37 and a fifty-two week high of $17.17.

AEON Biopharma (NASDAQ:AEON) last issued its quarterly earnings data on Friday, March 29th. The company reported ($0.71) earnings per share (EPS) for the quarter. Analysts forecast that AEON Biopharma will post -1.18 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Northern Trust Corp grew its holdings in AEON Biopharma by 53.4% during the fourth quarter. Northern Trust Corp now owns 49,819 shares of the company’s stock valued at $359,000 after purchasing an additional 17,341 shares during the period. Formidable Asset Management LLC acquired a new position in AEON Biopharma during the third quarter valued at approximately $360,000. Vanguard Group Inc. acquired a new position in AEON Biopharma during the third quarter valued at approximately $1,085,000. Finally, Atalaya Capital Management LP acquired a new position in AEON Biopharma during the third quarter valued at approximately $19,827,000. Institutional investors and hedge funds own 22.78% of the company’s stock.

AEON Biopharma Company Profile

AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine.